中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

显著肝纤维化的非创伤性诊断进展

蔡卫民

引用本文:
Citation:

显著肝纤维化的非创伤性诊断进展

详细信息
  • 中图分类号: R575.2

Noninvasive diagnosis of significant liver fibrosis

  • 摘要: 回顾血清肝纤维化指标的研究历史,介绍几年来肝纤维化非创伤诊断进展。讨论如何去诊断显著性肝纤维化。血清学指标和瞬时弹性图联合应用,有望更好的诊断肝纤维化。

     

  • [1]贾继东, 李海.肝脏纤维化基础和临床研究进展[J].中华肝脏病杂志, 2009, 17 (1) :5-6.
    [2] 陆伦根, 曾民德.肝纤维化的非创伤性诊断和评估[J].中华肝脏病杂志, 2008, 16 (3) :164-168.
    [3]Guha IN, Rosenberg WM.Noninvasive assessment of liver fibrosis:serum marker, imaging, and other modalities[J].Clin liver Dis, 2008, 12 (4) :883-900.
    [4]Manning DS, Afdhal NH.Diagnosis and Quantitation of fibrosis[J].Gastraenterology, 2008, 134 (6) :1670-1681.
    [5]蔡卫民.临床肝纤维化学[M].西安, 陕西人民出版社, 2010:98-162.
    [6]European Association For the Study of the Liver.EASL ClinicalPractice Guidelines:management of chronic hepatitis B[J].JHepatol, 2009, 50 (2) :227-242.
    [7]蔡卫民, 郑敏, 翁红雷, 等.慢性肝炎患者血清纤维化指标的检测及其意义[J].中华内科杂志, 2001, 40 (7) :448-451.
    [8]蔡卫民, 陶君, 翁红雷, 等.血清纤维化指标的影响因素分析[J].中华肝脏病杂志, 2003, 11 (1) :23-25.
    [9]蔡卫民, 张彬彬, 翁红雷, 等.八项肝纤维化血清标志物比较研究[J].中华肝脏病杂志, 2004, 12 (4) :219-222.
    [10]Zeng MD, Lu LG, Mao YM, et al.Prediction of signifilant fibrosis inHBeAg-positive patients with chronic hepatitis B by a noninvasivemodel[J].Hepatology, 2005, 42 (6) :1437-1445.
    [11]张文胜, 王宝恩, 王泰龄, 等.慢性乙型肝炎肝纤维化无创性诊断模型的建立[J].中华肝脏病杂志, 2006, 14 (3) :169-173.
    [12]郑瑞丹, 周琨, 咸建春, 等.慢性乙型肝炎病毒感染患者肝纤维化非创伤性诊断模型的应用评价[J].肝脏, 2008, 13 (6) :451-455.
    [13]Fontana RJ, Goodman ZD, Dienstag JL, et al.Relationship ofserum fibrosis markers with liver fibrosis stage and collagencontent in patients with advanced chronic hepatitis C[J].Hepatology, 2008, 47 (3) :789-798.
    [14]Rossi E, Adams L, Prins A, et al.Validation of the Fibro Testbiochemical markers score in assessing liver fibrosis in hepatitis Cpatients[J].Clin Chem, 2003, 49 (2) :450-454.
    [15]桂红莲, 谢青, 王晖, 等.Fribro Test-ActiTest对慢性乙型肝炎肝纤维化和炎症的诊断价值[J].中华肝脏病杂志, 2008, 16 (12) :897-901.
    [16]Naveau S, Gaude G, Asnacios A, et al.Diagnostic and prognosticvalues of noninvasive biomarkers of fibrosis in patients withalcoholic liver disease[J].Hepatology, 2009, 49 (1) :97-105.
    [17]Sebastiani G, Halfon P, Castera L, et al.SAFE biopsy:a validatedmethod for large-scale staging of liver fibrosis in chronic hepatitisC[J].Hepatology, 2009, 49 (6) :1821-1827.
    [18]Sebastiani G, Holfan P, Castera L, et al.Effect of prevalence ofliver fibrosis stages in the performance of non-invasive fibrosisbiomarkers in chronic liver diseases (CLDS) :Results of a large-scale, international study[J].Hepatology, 2009, 50 (Suppl 4) :404A.
    [19]Gressner OA, Beer N, Jodlowski A, et al.Impact of qualitycontrol accepated inter-laboratory and intreanalytical variabilityon balculated fibrotest/Actitest scores for the non-invasiveassessment of liver fibrosis[J].Hepatology, 2009, 50 (suppl 4) :88A.
    [20]Huang H, Shiffman ML, Cheung RC, et al.Identification of twogene variant associated with risk of advanced fibrosis in patiens withchronic hepatitis C[J].Gastroenterology, 2006, 130 (6) :1679-1687.
    [21]Huang H, Shiffman ML, friedmen S, et al.A 7 gene signatureidentifies the risk of developing cirrhosis in patients with chronichepatitis C[J].Hepatology, 2007, 46 (2) :297-306.
    [22]Marcolongo M, Young B, Dal Pero F, et al.A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patientswith initially mild chroinic hepatitis C[J].Hepatology, 2009, 50 (4) :1038-1044.
    [23]Gatti D, Maki A, Chesler EJ, et al.Genome-level analysisof genetic regulation of liver gene expression networks[J].Hepatology, 2007, 46 (2) :548-557.
    [24]Zheng M, Cai WM, Zhao JK, et al.Determination of serum levels ofYKL-40 and hyaluronic acid in patients with hepatic fibrosis dueto schistosomiasis japonica and appraisal of their chinical value[J].Acta Trop, 2005, 96 (2-3) :148-152.
    [25]Lai KKY, Klippakkam D, Beretta L.Comprehensive and quantitativeproteome profiling of mouse liver and plasma[J].Hepatology, 2008, 47 (3) :1043-1051.
    [26]Molleken C, sitek B, Henkel C, et al.Detection of novel biomarkersof liver cirrhosis by proteomic analysis[J].Hepatology, 2009, 49 (4) :1257-1266.
    [27]Huwart L, Sempoux C, Vicaut E, et al.Magnetic resonanceelastography for the noninvasive staging of liver fibrosis[J].Gastroenterology, 2008, 135 (1) :32-40.
    [28]Lucidarme D, Foucher J, Le Bail B, et al.Factors of accuracy oftransient elastography (fibroscan) for the diagnosis of liver fibrosisin chronic hepatitis C[J].Hepatology, 2009, 49 (4) :1083-1089.
    [29]Masuzaki R, Tateishi R, Yoshida H, et al.Prospective riskassessment for hepatocellular carcinoma development in patientswith chronic hepatitis C by transient elastography[J].Hepatology, 2009, 49 (6) :1954-1961.
    [30]Carróin JA, Torres F, Crespo G, et al.Liver stiffness idenifies twodifferent patterns of fibrosis progression in patients with hepatitisC Virus recurrence after liver transplantation[J].Hepatology, 2010, 51 (1) :23-34.
    [31]Wong VW, Vergniol J, Wong GL, et al.Diagnosis of fibrosis andcirrhosis using liver stiffness measurement in nonalcoholic fattyliver disease[J].Hepatology, 2010, 51 (2) :452-462.
    [32]Adams L.Transient elastography in nonalcoholic fatty liver disease:making sense of echos[J].Hepatology, 2010, 51 (2) :370-372.
    [33]Castera L, Foucher J, Bernard PH, et al.Pitfalls of liverstiffness measurement:a 5-year prospective study of 13, 369examinations[J].Hepatology, 2010, 51 (3) :828-835.
    [34]Fung J, Lai CL, But D, et al.Prevalence of fibrosis and cirrhosis inchronic hepatitis B:implication for treatment and management[J].Am J Gastroenterol, 2008, 103 (6) :1421-1426.
  • 加载中
计量
  • 文章访问数:  5604
  • HTML全文浏览量:  7
  • PDF下载量:  2069
  • 被引次数: 0
出版历程
  • 出版日期:  2011-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回